- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02085889
Fructose and Lactose Intolerance and Malabsorption in Functional Gastrointestinal Disorders
Fructose and Lactose Intolerance and Malabsorption: the Relationship Between Metabolism and Symptoms in Functional Gastrointestinal Disorders
Background: The association of fructose and lactose intolerance and malabsorption with the symptoms of different functional gastrointestinal disorders (FGID) is unclear. The mechanisms behind the multi-organ symptoms remain unclear. Both FGID and saccharide intolerances are common (>10% of any given population). Dietary modification based on intolerance diagnostics could provide an effective treatment for FGID, which are otherwise difficult to treat.
Aim: To investigate the prevalence and interrelationships of fructose and lactose intolerance (symptom induction) and malabsorption (breath test gas production) and their association with clinical GI as well as non-GI symptoms in FGID and the outcome of standard dietary intervention. Mechanisms related to symptom genesis will be investigated using metabolomic analysis of plasma and urine by gas chromatography/time-of-flight mass spectrometry (GC/TOFMS).
Methods: Fructose and lactose intolerance (defined by positive symptom index) and malabsorption (defined by increased hydrogen/methane) will be determined in successive male and female FGID patients in a single center using breath-testing. Symptoms will be recorded using standardised questionnaires and the Rome III criteria. The prevalence of the intolerances in the different FGID subgroups and the associations between breath testing results, clinical symptoms and the outcome of dietary modification will be assessed. Factors predictive of the outcome of dietary modulation will be screened for. GC/TOFMS will be used to assess the human and microbial metabolome in urine and plasma.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Bern, Switzerland
- Recruiting
- Gastoenterology Group Practice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- Patients with functional GI disorders according to ROME 3 criteria
- Without evidence of organic disease by standardised testing in GI practice.
Exclusion criteria:
- Current or relevant history of organic disease.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
food intolerance
lactose intolerance fructose intolerance neither intolerance
|
observational
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number with adequate symptom relief
Time Frame: 6-12 weeks
|
adequate symptom relief in response to reduction of fermentable sugars
|
6-12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association between adequate symptom relief and test variables
Time Frame: 6-12 weeks
|
association between demographic, breath test and metabolomic factors and adequate relief due to dietary modification
|
6-12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Clive Wilder-Smith, MD, Brain-Gut Research Group
Publications and helpful links
General Publications
- Wilder-Smith CH, Drewes AM, Materna A, Olesen SS. Extragastrointestinal Symptoms and Sensory Responses During Breath Tests Distinguish Patients With Functional Gastrointestinal Disorders. Clin Transl Gastroenterol. 2020 Aug;11(8):e00192. doi: 10.14309/ctg.0000000000000192.
- Wilder-Smith CH, Olesen SS, Materna A, Drewes AM. Fermentable Sugar Ingestion, Gas Production, and Gastrointestinal and Central Nervous System Symptoms in Patients With Functional Disorders. Gastroenterology. 2018 Oct;155(4):1034-1044.e6. doi: 10.1053/j.gastro.2018.07.013. Epub 2018 Sep 3.
- Wilder-Smith CH, Olesen SS, Materna A, Drewes AM. Breath methane concentrations and markers of obesity in patients with functional gastrointestinal disorders. United European Gastroenterol J. 2018 May;6(4):595-603. doi: 10.1177/2050640617744457. Epub 2017 Nov 15.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BGRG-2415b
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fructose Intolerance
-
Maastricht University Medical CenterPfizerCompleted
-
University of LausanneCompletedGlucose Metabolism Disorders | Fructose Metabolism, Inborn Errors | Hereditary Fructose Intolerance
-
Augusta UniversityTerminatedDietary Fructose IntoleranceUnited States
-
University of LausanneUniversity of LiegeCompletedHereditary Fructose IntoleranceBelgium
-
Augusta UniversityCompletedGlucose Intolerance | Fructose Intolerance | Lactose Intolerance | Small Intestinal Bacterial OvergrowthUnited States
-
Sciotec Diagnostic Technologies GmbHAustrian Research Promotion AgencyCompletedFructose MalabsorptionAustria
-
Sciotec Diagnostic Technologies GmbHNot yet recruitingFructose IntoleranceAustria
-
Augusta UniversityUniversity of Iowa; Teikyo UniversityRecruitingFructose IntoleranceUnited States
-
Augusta UniversityUnknownFructose IntoleranceUnited States
-
University Hospital of North NorwayNordlandssykehuset HFCompletedIrritable Bowel Syndrome | Fructose MalabsorptionNorway
Clinical Trials on no intervention: observational study
-
Drexel UniversityCompletedOsteoporosisUnited States
-
The Aurum Institute NPCKarolinska Institutet; Ludwig-Maximilians - University of Munich; University... and other collaboratorsUnknownRespiratory Tract Infections | Tuberculosis, PulmonaryMozambique, South Africa, Tanzania, Gambia
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
University Hospital, Basel, SwitzerlandCompletedPostoperative Complications | Intraoperative Complications | Patient Safety | Risk ManagementNew Zealand, Switzerland, United States, Netherlands, Spain, Austria, Turkey, United Kingdom, Australia, Greece, Ireland, Italy
-
Hôpital Necker-Enfants MaladesUnknown
-
Liverpool School of Tropical MedicineLondon School of Hygiene and Tropical Medicine; Wellcome Trust; University of... and other collaboratorsRecruitingKidney Diseases | Chronic Kidney Diseases | Non-communicable Disease | Non-Communicable Chronic DiseasesMalawi
-
Nanfang Hospital of Southern Medical UniversityThe First Affiliated Hospital of Anhui Medical University; Xiangya Hospital... and other collaboratorsRecruiting
-
RenJi HospitalNot yet recruitingEnd Stage Renal Disease on DialysisChina
-
Nanowear Inc.RecruitingElective Surgical ProceduresUnited States
-
Sheffield Teaching Hospitals NHS Foundation TrustNational Institute for Health Research, United Kingdom; Alexion Pharmaceuticals...Completed